EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L5	2571	((544/362) or (544/370) or (544/372) or (544/373)).CCLS.	US-PGPUB; USPAT	OR	OFF	2006/03/06 14:39
L6	143	biphenyl-4-ylmethyl	US-PGPUB; USPAT	OR	OFF	2006/03/06 14:41
L7	5	l5 and l6	US-PGPUB; USPAT	OR	OFF	2006/03/06 14:41
L8	908	(544/364).CCLS.	US-PGPUB; USPAT	OR	OFF	2006/03/06 14:42
L9	441	pyridinyl near3 benzyl	US-PGPUB; USPAT	OR	OFF	2006/03/06 14:42
L10	2238	pyridyl near3 benzyl	US-PGPUB; USPAT	OR	OFF	2006/03/06 14:43
L11	45	l8 and (l9 or l10)	US-PGPUB; USPAT	OR	OFF	2006/03/06 14:43

C:\Documents and Settings\EBernhardt\My Document

Part 2





chain nodes :
7 15 16 17 18 19 20 21 22 28 30 32 33 34 35 36 37 39
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
ring/chain nodes :
23
chain bonds :
1-37 1-39 2-35 2-36 3-28 4-30 4-32 5-33 5-34 6-7 7-10 15-16 15-17 15-18
19-20 20-21 20-22 20-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 1-37 1-39 2-3 2-35 2-36 3-4 3-28 4-5 4-30 4-32 5-6 5-33 5-34 6-7
7-10 15-18 19-20 20-21 20-22 20-23
exact bonds :
15-16 15-17
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

G1:OH,X,[*1]

G2:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 26:CLASS 28:CLASS 30:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS
36:CLASS 37:CLASS 39:CLASS
Generic attributes :

```
    7:
    Saturation              : Unsaturated
    Number of Carbon Atoms  : less than 7
    Type of Ring System     : Monocyclic

Element Count :
    Node 7: Limited
        N,N1-2
        O,O0
        S,S0
```

```
=> s l1
SAMPLE SEARCH INITIATED 13:15:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    40528 TO ITERATE

  4.9% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       798539 TO   822581
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:16:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   808395 TO ITERATE

100.0% PROCESSED   808395 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.10

L3            3 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   167.38     167.59

FILE 'CAPLUS' ENTERED AT 13:16:15 ON 06 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Mar 2006  VOL 144 ISS 11
FILE LAST UPDATED: 5 Mar 2006  (20060305/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            2 L3

=> d l4 1-2 bib abs hitstr

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:564657  CAPLUS
```

DN 143:97383
TI Preparation of pyrazines as protein kinase, especially pUL-97 kinase, inhibitors for treatment of infectious diseases, particularly human cytomegaloviral infections
IN Eikhoff, Jan Eike; Ashton, Mark Richard; Courtney, Stephen Martin; Yarnold, Christopher John; Varrone, Maurizio; Loke, Pui Leng; Herget, Thomas; Schwab, Wilfried; Hafenbradl, Doris
PA Axxima Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005058876	A1	20050630	WO 2004-EP14371	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI EP 2003-29038	A	20031216		
US 2003-530612P	P	20031219		

OS MARPAT 143:97383
GI



I



II

AB The invention is related to the prepn. of title compds. I, and/or

stereoisomeric forms, prodrugs, and/or pharmaceutically acceptable salts [wherein R1, R2 = independently H, F, Cl, BR, OH, (un)substittued alk(en/yn)yl, etc.; R3 = (un)substituted cycloalkyl, hetero/aryl, heterocyclyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, hetero/aryl, heterocyclyl, etc.; R4NR5 = (un)substituted mononitrogen or dinitrogen ring] as protein kinase inhibitors for use in the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke and esp. for the treatment of herpesviral induced infections, including opportunistic infections and infections and diseases caused by human cytomegalovirus (HCMV). For example, II was prepd. by monoacylation of 2,6-dichloropyrazine with 1-(4-pyridinyl)piperazine and coupling of the chloride with (4-aminocarbonylphenyl)boronic acid. I have an inhibitory effect on the protein kinase activity of various protein kinases, such as pUL-97, EGFR, , etc. I were potent inhibitors of HCMV replication in cell cultures; I showed inhibition of HCMV replication in HFF cells (IC50 < 3 .mu.M). I did not show any or low toxicity up to concns. of 10 .mu.M in HFF cells.

IT **856002-34-1P**, (Furan-2-yl)[6'-(3-hydroxymethylphenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]methanone **856002-39-6P**, 1-[3-[4-[2-(Pyrrolidin-1-yl)ethyl]-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-6'-yl]phenyl]methanol
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of pyrazines as protein kinase, esp. pUL-97 kinase, inhibitors for treatment of infectious diseases, particularly human cytomegaloviral infections)

RN 856002-34-1 CAPLUS
CN Piperazine, 1-(2-furanylcarbonyl)-4-[6-[3-(hydroxymethyl)phenyl]pyrazinyl]- (9CI) (CA INDEX NAME)



RN 856002-39-6 CAPLUS
CN Benzenemethanol, 3-[6-[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]pyrazinyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:116083 CAPLUS
DN 142:198092
TI A preparation of 2-aminopyrimidine derivatives, useful as histamine H4 receptor antagonists
IN Sato, Hiroki; Fukushima, Keiko; Shimazaki, Makoto; Urbahns, Klaus; Sakai, Katsuya; Gantner, Florian; Bacon, Kevin
PA Bayer Healthcare AG, Germany
SO Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1505064	A1	20050209	EP 2003-17810	20030805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2005014556	A1	20050217	WO 2004-EP8225	20040723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI EP 2003-17810 A 20030805
OS CASREACT 142:198092; MARPAT 142:198092
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a prepn. of novel 2-aminopyrimidine derivs. of formula I [wherein: R1 is pyrrolidine or piperazine deriv. attached to the pyrimidine ring via nitrogen atom; R2 is Ph or naphthyl deriv.], useful as histamine H4 receptor antagonists. The 2-aminopyrimidine derivs. of the present invention are useful for treatment and prophylaxis of diseases such as asthma, rhinitis, allergic diseases, chronic obstructed pulmonary

disease (CORD), atherosclerosis, and rheumatoid arthritis. For instance, 2-aminopyrimidine deriv. II.bul.3HCl was prepd. via amination of 2-amino-4,6-dichloropyrimidine by aminopyrrolidine deriv. III, phenylation of the obtained amino(aminopyrrolidinyl)pyrimidine deriv. by PhB(OH)2, and subsequent N-cleavage (yields: amination - 66%, phenylation - 89%). For instance, IC50 for the invention compd. IV.bul.3HCl was < 20 nM.

IT **838872-00-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-aminopyrimidine derivs. useful as histamine H4 receptor antagonists)

RN 838872-00-7 CAPLUS
CN Benzenemethanol, 3-[2-amino-6-(4-methyl-1-piperazinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.14	178.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

FILE 'CAOLD' ENTERED AT 13:17:25 ON 06 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3

L5 0 L3

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	179.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:17:34 ON 06 MAR 2006